YUMAB and InSCREENeX in search of new targets and compounds against pancreatic cancer

Companies work together on innovative approaches to individual tumor research in exPDITE funding project

31-Jul-2023 - YUMAB GmbH, a German biotechnology company specializing in contract research of therapeutic antibodies, announces its collaboration with InSCREENeX GmbH under the "exPDITE" funding project. The goal of the collaboration is to enable improved drug development for the individual treatment of ...

Immortal cells for tailor-made active substances

12-Mar-2018 - When scientists discover a new active substance, e.g. for use against a pathogen, they usually study its exact effect in cultured cells. But there is a lack of suitable test systems that simulate body tissues, because cells rapidly lose their specific properties once they are away from their ...

InSCREENeX Appoints Henrik L. Luessen as Chief Business Officer

17-Jun-2010 - InSCREENeX GmbH announced the appointment of Dr. Henrik L. Luessen to the position of Chief Business Officer. He will be responsible for business and strategic development with a particular focus on launching the company’s SCREENflex™ and CI-SCREEN™ technologies which can significantly improve ...

HZI and Ascenion Help Launch New Spin-off InSCREENex GmbH

29-Mar-2010 - With InSCREENex GmbH, a new spin-off from the Helmholtz Centre for Infection Research (HZI) enters the market. As a service partner, the company develops customized cells for the biopharmaceutical industry with wide-ranging applications in drug discovery and development. InSCREENex’s core ...